Nonalcoholic Steatohepatitis: KOL Insight Which NASH products are most likely to succeed as the new treatment paradigm develops?
At this stage of the game, it's unclear if one drug is going dominate the market. With significant clinical unmet need, plenty of room exists for diverse approaches. Nonalcoholic Steatohepatitis: KOL Insight reveals critical US and European KOL views on pipeline products, biomarkers, combination therapy, prescribing decision factors and what they see as emerging clinical benefits and challenges. Learn more.
The US government said Friday that it plans to implement a five-year action plan to combat the threat posed by antibiotic-resistant bacteria. According to the White House, part of the plan involves... Read More >>